Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 3/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 3/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 3/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 3/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 3/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 3/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | PARP1 | P09874 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TNKS | O95271 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | GPR3 | P46089 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495630 | 1.00 | KDM4E (1.00) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| Bicarbonate SCHEMBL7779718 | 0.89 | KDM4E (0.79) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8873559 | 0.88 | KDM4E (0.78) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8873438 | 0.81 | PARP1 (0.74) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4558727 | 0.80 | KDM4E (0.67) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29367508 | 0.80 | KDM4E (0.67) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL37951 | 0.80 | KDM4E (0.67) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL30832797 | 0.78 | KDM4E (0.63) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL30275219 | 0.78 | KDM4E (0.63) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL4647780 | 0.78 | KDM4E (0.63) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | claimed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | claimed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | claimed |
| CN-108349953-B | Pesticidal compositions and methods | 孟山都技术公司 | 2022-06-17 | — | — | CN | claimed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | claimed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | claimed |
| CN-108383828-A | 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative | 阿勒根公司 | 2018-08-10 | — | — | CN | claimed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | claimed |
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | claimed |
| EP-3286174-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-02-28 | — | — | EP | claimed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | claimed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | claimed |
| WO-1996019476-A1 | NOVEL QUINOXALINES AND DRUGS PREPARED THEREFROM | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-27 | — | — | WO | claimed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | claimed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | claimed |
| JP-H08501283-A | — | — | 1996-02-13 | — | — | JP | claimed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | claimed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0572852-A1 | Quinoxalin-2,3(1H,4H)-diones used as medicine | BASF Aktiengesellschaft (DE) | 1993-12-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | KDM4E 4433/4885GRIN2D 42/4885GRIN3B 96/4885 |
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | KDM4E 4204/4885GRIN2D 68/4885GRIN3B 61/4885 |
| US-10633336-B2 | Dopamine D2 receptor ligands | DRD2, ARRB1, DRD3 | KDM4E 4325/4885GRIN2D 85/4885GRIN3B 75/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | KDM4E 4204/4885GRIN2D 68/4885GRIN3B 61/4885 |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | KDM4E 4204/4885GRIN2D 68/4885GRIN3B 61/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | KDM4E 4204/4885GRIN2D 68/4885GRIN3B 61/4885 |
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | KDM4E 2426/4885GRIN2D 4459/4885GRIN3B 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.